MannKind to Present at the H.C. Wainwright Global Life Sciences Conference
April 02 2019 - 6:00AM
MannKind Corporation (NASDAQ: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension, announced today that it will
be featured as a presenting company at the H.C. Wainwright Global
Life Sciences Conference at 12:10 PM (CET) on April 8, 2019.
The conference is being held at the Grosvenor House in London,
UK.
Michael Castagna, Chief Executive Officer, of
MannKind Corporation, will provide an overview of the Company's
business during the live presentation and will participate in
one-on-one meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would
like to attend the Company’s presentation, please click on the
following link (www.hcwevents.com ) to register for the
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
The presentation will be webcast live. To
access the webcast, please visit www.hcwevents.com.
Interested parties can also access a link to the live webcast of
the presentation from the News & Events section of the
Company's website at http://www.mannkindcorp.com. The webcast
replay will remain available for 14 days following the live
presentation.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company Contact:Rose AlinayaSVP Investor
Relations818-661-5000ir@mannkindcorp.com
Source: MannKind Corporation
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2024 to Oct 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Oct 2023 to Oct 2024